Vitamin D regulates macrophage cholesterol metabolism in diabetes

Journal of Steroid Biochemistry and Molecular Biology

Volumn 121, Issue 1-2, 2010, Pages 430-433

  Riek, Amy E ^a   Oh, Jisu ^a   Bernal Mizrachi, Carlos ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Diabetes; Macrophage cholesterol metabolism; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ACETYLATED LOW DENSITY LIPOPROTEIN CHOLESTEROL; CD36 ANTIGEN; CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN SR A1; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VITAMIN D;

ANTIGEN EXPRESSION; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DIABETES MELLITUS; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; FOAM CELL; HUMAN; HYPERTENSION; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VITAMIN BLOOD LEVEL; ANIMAL; ATHEROSCLEROSIS; COMPLICATION; GENE EXPRESSION REGULATION; METABOLISM; RISK;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES COMPLICATIONS; DIABETES MELLITUS; FOAM CELLS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INSULIN; MACROPHAGES; RISK; VITAMIN D;

EID: 77954758385     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.03.018     Document Type: Article

References (45)

1. Gregg E.W., Gu Q., Cheng Y.J., Narayan K.M., Cowie C.C. Mortality trends in men and women with diabetes, 1971 to 2000. Ann. Intern. Med. 2007, 147(3):149-155.
2. Gorina Y., Lentzer H. Multiple causes of death in old age. Aging Trends 2008, vol 9. National Center for HealthStatistics.
3. Dluhy R.G., McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N. Engl. J. Med. 2008, 358(24):2630-2633.
4. Martins D., Wolf M., Pan D., Zadshir A., Tareen N., Thadhani R., Felsenfeld A., Levine B., Mehrotra R., Norris K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 2007, 167(11):1159-1165.
5. Dobnig H., Pilz S., Scharnagl H., Renner W., Seelhorst U., Wellnitz B., Kinkeldei J., Boehm B.O., Weihrauch G., Maerz W. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 2008, 168(12):1340-1349.
6. Kim D.H., Sabour S., Sagar U.N., Adams S., Whellan D.J. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am. J. Cardiol. 2008, 102(11):1540-1544.
7. Kendrick J., Targher G., Smits G., Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 2009, 205(1):255-260.
8. Melamed M.L., Michos E.D., Post W., Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 2008, 168(9):1629-1637.
9. Cigolini M., Iagulli M.P., Miconi V., Galiotto M., Lombardi S., Targher G. Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diab. Care 2006, 29(3):722-724.
10. Chonchol M., Cigolini M., Targher G. Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction. Nephrol. Dial. Transplant. 2008, 23(1):269-274.
11. Wang T.J., Pencina M.J., Booth S.L., Jacques P.F., Ingelsson E., Lanier K., Benjamin E.J., D'Agostino R.B., Wolf M., Vasan R.S. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117(4):503-511.
12. Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 2008, 168(11):1174-1180.
13. Sugden J.A., Davies J.I., Witham M.D., Morris A.D., Struthers A.D. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diab. Med. 2008, 25(3):320-325.
14. Kodama T., Reddy P., Kishimoto C., Krieger M. Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 1988, 85(23):9238-9242.
15. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 1993, 268(16):11811-11816.
16. Nozaki S., Kashiwagi H., Yamashita S., Nakagawa T., Kostner B., Tomiyama Y., Nakata A., Ishigami M., Miyagawa J., Kameda-Takemura K., et al. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J. Clin. Invest. 1995, 96(4):1859-1865.
17. Suzuki H., Kurihara Y., Takeya M., Kamada N., Kataoka M., Jishage K., Ueda O., Sakaguchi H., Higashi T., Suzuki T., Takashima Y., Kawabe Y., Cynshi O., Wada Y., Honda M., Kurihara H., Aburatani H., Doi T., Matsumoto A., Azuma S., Noda T., Toyoda Y., Itakura H., Yazaki Y., Kodama T., et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997, 386(6622):292-296.
18. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93(2):241-252.
19. Oram J.F. ATP-binding cassette transporter A1 and cholesterol trafficking. Curr. Opin. Lipidol. 2002, 13(4):373-381.
20. Acton S.L., Scherer P.E., Lodish H.F., Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 1994, 269(33):21003-21009.
21. Tall A.R., Costet P., Wang N. Regulation and mechanisms of macrophage cholesterol efflux. J. Clin. Invest. 2002, 110(7):899-904.
22. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 2006, 86(2):515-581.
23. Koeffler H.P., Amatruda T., Ikekawa N., Kobayashi Y., DeLuca H.F. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. Cancer Res. 1984, 44(12 Pt 1):5624-5628.
24. Giulietti A., van Etten E., Overbergh L., Stoffels K., Bouillon R., Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile: 1, 25-dihydroxyvitamin D(3) works as anti-inflammatory. Diab. Res. Clin. Pract. 2007, 77(1):47-57.
25. Jouni Z.E., McNamara D.J. Lipoprotein receptors of HL-60 macrophages. Effect of differentiation with tetramyristic phorbol acetate and 1,25-dihydroxyvitamin D3. Arterioscler. Thromb. 1991, 11(4):995-1006.
26. Suematsu Y., Nishizawa Y., Shioi A., Hino M., Tahara H., Inaba M., Morii H., Otani S. Effect of 1,25-dihydroxyvitamin D3 on induction of scavenger receptor and differentiation of 12-O-tetradecanoylphorbol-13-acetate-treated THP-1 human monocyte like cells. J. Cell. Physiol. 1995, 165(3):547-555.
27. Roullet J.B., Haluska M., Morchoisne O., McCarron D.A. 1,25-Dihydroxyvitamin D3-induced alterations of lipid metabolism in human monocyte-macrophages. Am. J. Physiol. 1989, 257(2 Pt 1):E290-E295.
28. Oh J., Weng S., Felton S.K., Bhandare S., Riek A., Butler B., Proctor B.M., Petty M., Chen Z., Schechtman K.B., Bernal-Mizrachi L., Bernal-Mizrachi C. 1,25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009, 120(8):687-698.
29. Zhao B., Song J., St Clair R.W., Ghosh S. Stable overexpression of human macrophage cholesteryl ester hydrolase results in enhanced free cholesterol efflux from human THP1 macrophages. Am. J. Physiol. Cell. Physiol. 2007, 292(1):C405-C412.
30. Han S., Liang C.P., DeVries-Seimon T., Ranalletta M., Welch C.L., Collins-Fletcher K., Accili D., Tabas I., Tall A.R. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell. Metab. 2006, 3(4):257-266.
31. Zhou J., Lhotak S., Hilditch B.A., Austin R.C. Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation 2005, 111(14):1814-1821.
32. DeVries-Seimon T., Li Y., Yao P.M., Stone E., Wang Y., Davis R.J., Flavell R., Tabas I. Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J. Cell. Biol. 2005, 171(1):61-73.
33. Erbay E., Babaev V.R., Mayers J.R., Makowski L., Charles K.N., Snitow M.E., Fazio S., Wiest M.M., Watkins S.M., Linton M.F., Hotamisligil G.S. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat. Med. 2009, 15(12):1383-1391.
34. Rahaman S.O., Lennon D.J., Febbraio M., Podrez E.A., Hazen S.L., Silverstein R.L. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell. Metab. 2006, 4(3):211-221.
35. Sumara G., Belwal M., Ricci R. " Jnking" atherosclerosis. Cell. Mol. Life Sci. 2005, 62(21):2487-2494.
36. Rader D.J., Pure E. Lipoproteins, macrophage function, and atherosclerosis: beyond the foam cell?. Cell. Metab. 2005, 1(4):223-230.
37. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., Glass C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 1998, 95(13):7614-7619.
38. Liang C.P., Han S., Senokuchi T., Tall A.R. The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ. Res. 2007, 100(11):1546-1555.
39. Bernal-Mizrachi L., Lovly C.M., Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc. Natl. Acad. Sci. USA 2006, 103:9220-9225.
40. Holick M.F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr. 2004, 79(3):362-371.
41. Pittas A.G., Lau J., Hu F.B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2007, 92(6):2017-2029.
42. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110(2):229-238.
43. Timms P.M., Mannan N., Hitman G.A., Noonan K., Mills P.G., Syndercombe-Court D., Aganna E., Price C.P., Boucher B.J. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?. QJM 2002, 95(12):787-796.
44. Norman P.E., Powell J.T. Vitamin D, shedding light on the development of disease in peripheral arteries. Arterioscler. Thromb. Vasc. Biol. 2005, 25(1):39-46.
45. Mathieu C., Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol. Med. 2002, 8(4):174-179.